Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Trypanosoma cruzi | trypanothione reductase, putative | Curated by TDR Targets | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | dihydrolipoyl dehydrogenase, apicoplast | trypanothione reductase, putative | 492 aa | 548 aa | 21.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | type I geranylgeranyltransferase beta subunit, putative | 0.0111 | 0.3551 | 1 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0076 | 0.1787 | 0.1751 |
Toxoplasma gondii | thioredoxin reductase | 0.0076 | 0.1787 | 0.4971 |
Toxoplasma gondii | prenyltransferase and squalene oxidase repeat-containing protein | 0.0111 | 0.3551 | 1 |
Mycobacterium tuberculosis | Halimadienyl diphosphate synthase | 0.0122 | 0.4094 | 1 |
Schistosoma mansoni | protein farnesyltransferase subunit beta | 0.0111 | 0.3551 | 0.3523 |
Entamoeba histolytica | protein farnesyltransferase beta subunit, putative | 0.0111 | 0.3551 | 1 |
Trichomonas vaginalis | protein farnesyltransferase alpha subunit, putative | 0.0041 | 0.0044 | 0.0123 |
Trypanosoma cruzi | protein farnesyltransferase, putative | 0.0111 | 0.3551 | 0.8661 |
Brugia malayi | glutathione reductase | 0.0076 | 0.1787 | 0.1751 |
Trypanosoma brucei | lanosterol synthase | 0.0122 | 0.4094 | 1 |
Trichomonas vaginalis | geranylgeranyl transferase type I beta subunit, putative | 0.0111 | 0.3551 | 1 |
Onchocerca volvulus | 0.0041 | 0.0044 | 0.5 | |
Trichomonas vaginalis | geranylgeranyl transferase type beta subunit, putative | 0.0111 | 0.3551 | 1 |
Trichomonas vaginalis | protein farnesyltransferase alpha subunit/RAB geranylgeranyl transferase alpha subunit, putative | 0.0041 | 0.0044 | 0.0123 |
Trichomonas vaginalis | geranylgeranyl transferase type II beta subunit, putative | 0.0111 | 0.3551 | 1 |
Leishmania major | trypanothione reductase | 0.0076 | 0.1787 | 0.4971 |
Trypanosoma cruzi | protein farnesyltransferase, putative | 0.0111 | 0.3551 | 0.8661 |
Trichomonas vaginalis | geranylgeranyl transferase type II beta subunit, putative | 0.0111 | 0.3551 | 1 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0076 | 0.1787 | 0.1751 |
Brugia malayi | Prenyltransferase and squalene oxidase repeat family protein | 0.0111 | 0.3551 | 0.3523 |
Plasmodium vivax | glutathione reductase, putative | 0.0076 | 0.1787 | 0.4971 |
Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.4359 | 0.4334 |
Plasmodium falciparum | thioredoxin reductase | 0.0076 | 0.1787 | 0.4971 |
Echinococcus granulosus | peptidyl glycine alpha amidating monooxygenase | 0.024 | 1 | 1 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0127 | 0.4359 | 0.4334 |
Loa Loa (eye worm) | prenyltransferase and squalene oxidase repeat family protein | 0.0111 | 0.3551 | 0.3523 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0063 | 0.1116 | 0.1077 |
Plasmodium falciparum | glutathione reductase | 0.0076 | 0.1787 | 0.4971 |
Loa Loa (eye worm) | hypothetical protein | 0.024 | 1 | 1 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0076 | 0.1787 | 0.4305 |
Plasmodium vivax | farnesyltransferase beta subunit, putative | 0.0111 | 0.3551 | 1 |
Schistosoma mansoni | peptidylglycine monooxygenase | 0.0127 | 0.4359 | 0.4334 |
Leishmania major | farnesyltransferase beta subunit | 0.0111 | 0.3551 | 1 |
Schistosoma mansoni | peptidyl-glycine monooxygenase | 0.024 | 1 | 1 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0076 | 0.1787 | 0.4971 |
Trichomonas vaginalis | protein farnesyltransferase alpha subunit, putative | 0.0041 | 0.0044 | 0.0123 |
Trypanosoma brucei | trypanothione reductase | 0.0076 | 0.1787 | 0.4305 |
Trypanosoma cruzi | lanosterol synthase, putative | 0.0122 | 0.4094 | 1 |
Trypanosoma cruzi | lanosterol synthase, putative | 0.0122 | 0.4094 | 1 |
Giardia lamblia | Prenyltransferase | 0.0111 | 0.3551 | 1 |
Echinococcus granulosus | protein farnesyltransferase subunit beta | 0.0111 | 0.3551 | 0.3523 |
Leishmania major | lanosterol synthase, putative | 0.0092 | 0.2579 | 0.7229 |
Echinococcus multilocularis | peptidyl glycine alpha amidating monooxygenase | 0.024 | 1 | 1 |
Trichomonas vaginalis | protein farnesyltransferase alpha subunit, putative | 0.0041 | 0.0044 | 0.0123 |
Trichomonas vaginalis | geranylgeranyl transferase type II beta subunit, putative | 0.0111 | 0.3551 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0076 | 0.1787 | 0.1751 |
Plasmodium falciparum | protein farnesyltransferase subunit beta | 0.0111 | 0.3551 | 1 |
Plasmodium vivax | conserved Plasmodium protein, unknown function | 0.0081 | 0.2037 | 0.5683 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, N-terminal domain containing protein | 0.0065 | 0.1212 | 0.1173 |
Loa Loa (eye worm) | glutathione reductase | 0.0076 | 0.1787 | 0.1751 |
Echinococcus multilocularis | protein farnesyltransferase subunit beta | 0.0111 | 0.3551 | 0.3523 |
Schistosoma mansoni | dopamine-beta-monooxygenase | 0.0127 | 0.4359 | 0.4334 |
Trypanosoma brucei | protein farnesyltransferase beta subunit | 0.0111 | 0.3551 | 0.8661 |
Brugia malayi | Thioredoxin reductase | 0.0076 | 0.1787 | 0.1751 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | = 24.7 uM | Cytotoxicity against BALB/c mouse spleen cells | ChEMBL. | 17081761 |
IC50 (functional) | = 3.96 uM | Inhibition of LPS-induced BALB/c mouse B cell proliferation | ChEMBL. | 17081761 |
IC50 (functional) | = 10 uM | Inhibition of ConA-induced BALB/c mouse T cell proliferation | ChEMBL. | 17081761 |
Ratio CC50/IC50 (functional) | = 2 | Selectivity index, ratio of CC50 for BALB/c mouse spleen cells to IC50 for BALB/c mouse T cells | ChEMBL. | 17081761 |
Ratio CC50/IC50 (functional) | = 6 | Selectivity index, ratio of CC50 for BALB/c mouse T cells to IC50 for BALB/c mouse B cells | ChEMBL. | 17081761 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.